Should You Buy This Stock After a Regulatory Setback?

It's not uncommon for companies to face regulatory setbacks -- and It's not the end of the world. Biotech investors aren't fond of regulatory delays. Brand-new products have a limited shelf life before they run out of patent protection. The less time they spend on the market, the less they will generate in sales. But in this The past two-and-a-half years have been rough for Moderna (MRNA 1.58%). Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche t ...